How many drugs treat Tear film insufficiency?

Drug Landscape tracks 9 marketed treatments for Tear film insufficiency (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/tear-film-insufficiency.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tear film insufficiency — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tear film insufficiency (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tear film insufficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xiidra	LIFITEGRAST	Bausch Health	Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]	Intercellular adhesion molecule 1	2016-01-01
Up4U	DIQUAFOSOL	Santen Pharmaceutical		P2Y purinoceptor 2	2010-01-01
Miralax	Macrogol	Braintree	Osmotic Laxative [EPC]		1984-01-01
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
Sandimmune	Ciclosporin	Novartis	Calcineurin Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	1983-01-01
Xiidra	Xiidra	Qilu Pharmaceutical Co., Ltd.		Integrin alpha-L/beta-2, Intercellular adhesion molecule 1
Neoral	Neoral	Novartis Pharmaceuticals		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
Cyclosporin	Cyclosporin	Karolinska University Hospital		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2
ciclosporine	ciclosporine	Hospices Civils de Lyon		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Tear film insufficiency
Bausch Health · 1 drug in Tear film insufficiency
Braintree · 1 drug in Tear film insufficiency
Hospices Civils de Lyon · 1 drug in Tear film insufficiency
Karolinska University Hospital · 1 drug in Tear film insufficiency
Novartis · 1 drug in Tear film insufficiency
Novartis AG (originally Sandoz) · 1 drug in Tear film insufficiency
Novartis Pharmaceuticals · 1 drug in Tear film insufficiency
Qilu Pharmaceutical Co., Ltd. · 1 drug in Tear film insufficiency
Santen Pharmaceutical · 1 drug in Tear film insufficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tear film insufficiency:

Cite this brief

Drug Landscape (2026). Tear film insufficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tear-film-insufficiency. Accessed 2026-06-10.

Tear film insufficiency full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing